sauth delhi call girls in Bhajanpura 🔝 9953056974 🔝 escort Service
Mixed dyslipidemia – pipeline review, h1 2012
1. Aarkstore.com announces, The Latest market research report is available in
its vast collection:
Mixed Dyslipidemia – Pipeline Review, H1 2012
You can also request for sample page of above mention reports on
sample@aarkstore.com
Summary
Global Markets Direct’s, Mixed Dyslipidemia - Pipeline Review, H1 2012, provides an
overview of the Mixed Dyslipidemia therapeutic pipeline. This report provides
information on the therapeutic development for Mixed Dyslipidemia, complete with
latest updates, and special features on late-stage and discontinued projects. It also
reviews key players involved in the therapeutic development for Mixed
Dyslipidemia. Mixed Dyslipidemia - Pipeline Review, H1 2012 is built using data and
information sourced from Global Markets Direct’s proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the
availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Mixed Dyslipidemia.
- A review of the Mixed Dyslipidemia products under development by companies
and universities/research institutes based on information derived from company
and industry-specific sources.
2. - Coverage of products based on various stages of development ranging from
discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined
therapeutics.
Table of contents:
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mixed Dyslipidemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Mixed Dyslipidemia 7
Mixed Dyslipidemia Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Mixed Dyslipidemia Therapeutics – Products under Development by Companies 13
Companies Involved in Mixed Dyslipidemia Therapeutics Development 14
Merck & Co., Inc. 14
Pronova BioPharma ASA 15
Intas Pharmaceuticals Ltd. 16
Ache Laboratorios Farmaceuticos S/A 17
Mixed Dyslipidemia – Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
MK-0524A - Drug Profile 24
Product Description 24
Mechanism of Action 24
3. R&D Progress 24
IN-SUPR-001 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NanoActive Rosuvastatin - Drug Profile 27
List of Figures
List of Tables are also include.
For more related Reports Plz follow The link:
Pipeline Review, H1 2012
http://www.aarkstore.com/search/viewresults.asp?search=Pipeline Review, H1
2012&PubId=&pagenum=1
Bacteremia – Pipeline Review, H1 2012
Staphylococcus Aureus Infections – Pipeline Review, H1 2012
Warts – Pipeline Review, H1 2012
Mixed Dyslipidemia – Pipeline Review, H1 2012
Gastroenteritis – Pipeline Review, H1 2012
Hypereosinophilic Syndrome – Pipeline Review, H1 2012
4. Familial Adenomatous Polyposis Coli – Pipeline Review, H1 2012
Tinnitus – Pipeline Review, H1 2012
Shock – Pipeline Review, H1 2012
Influenza B Infections – Pipeline Review, H1 2012
Search More Reports Related to This Category :
Pharmaceuticals and Healthcare
http://www.aarkstore.com/search/viewresults.asp?search=Pharmaceuticals and
Healthcare&PubId=&pagenum=1
For More details Plz do contact :
Aarkstore Enterprise
Lavanya
Phone:08149852585
Email: enquiry@aarkstore.com